period
appear
new
influenza
variant
pose
worldwid
pandem
threat
sinc
emerg
new
viru
human
case
report
mortal
rate
patient
infect
contact
poultri
visit
live
anim
market
howev
sporad
case
seem
result
human
human
transmiss
contrast
pandem
virus
fulminantli
enter
human
popul
caus
high
mortal
rate
season
influenza
virus
gener
caus
uncompl
transient
infect
human
viru
replic
local
upper
respiratori
tract
howev
fulli
develop
form
influenza
acut
respiratori
diseas
result
hospit
death
mainli
among
highrisk
group
worldwid
annual
epidem
result
three
five
million
case
sever
ill
death
reason
cdc
recommend
antivir
treatment
patient
suspect
influenza
risk
influenza
complic
without
previou
laboratori
confirm
known
influenza
viru
infect
often
accompani
viral
pathogen
depend
detect
method
qrtpcr
immunofluoresc
differ
ratio
coinfect
found
analysi
qrtpcr
reveal
influenza
b
posit
patient
found
least
one
concomit
respiratori
viral
infect
detect
frequenc
immunofluoresc
found
even
higher
potenti
concomit
viral
pathogen
influenza
viru
infect
includ
human
rhinoviru
hrv
respiratori
syncyti
viru
adenoviru
human
coronaviru
human
metapneumoviru
parainfluenza
viru
result
multipl
infect
specif
antiinfluenza
monotherapi
treat
influenza
viru
infect
infect
concomit
viral
pathogen
henc
therapi
often
fail
suffici
resolv
symptom
also
reflect
fact
neuraminidas
inhibitor
ni
highli
efficaci
anim
model
investig
influenza
monoinfect
show
lower
efficaci
influenza
symptom
clinic
trial
adult
natur
infect
therefor
high
medic
need
broadli
act
antivir
therapi
combin
specif
antiinfluenza
therapi
treatment
patient
suffer
upper
respiratori
tract
symptom
ideal
substanc
present
combin
complement
differ
mode
action
lead
treatment
provid
full
protect
broad
rang
differ
respiratori
virus
well
differ
influenza
strain
low
probabl
induc
escap
mutat
one
approach
broad
antivir
therapi
creation
protect
physic
barrier
nasal
caviti
use
carrageenan
carrageenan
high
molecular
weight
sulfat
polym
deriv
red
seawe
rhodophycea
extens
use
food
cosmet
pharmaceut
industri
gener
recogn
safe
fda
gra
review
three
main
form
carrageenan
commerci
use
kappa
iota
lambda
differ
degre
sulfat
solubl
gell
properti
antivir
mechan
carrageenan
base
interfer
viral
attach
consequ
viral
entri
inhibit
antivir
activ
depend
type
polym
well
viru
host
cell
review
publish
iotacarrageenan
potent
inhibitor
hrv
influenza
replic
demonstr
antivir
efficaci
iotacarrageenan
common
cold
virus
intranas
applic
sever
random
doubleblind
parallel
group
placebocontrol
clinic
trial
pool
analysi
two
studi
conduct
children
adult
reveal
patient
infect
respiratori
viru
intranas
treat
iotacarrageenan
show
day
faster
recoveri
common
cold
symptom
placebo
treat
patient
intentiontotreat
popul
antiinfluenza
activ
shown
subgroup
analysi
influenza
infect
patient
benefit
day
faster
recoveri
symptom
use
carrageenan
nasal
spray
associ
signific
reduct
influenza
viral
load
nasal
fluid
signific
increas
number
viru
free
patient
within
treatment
period
day
good
accord
literatur
observ
major
influenza
viru
infect
patient
suffer
concomit
respiratori
viral
infect
determin
realtim
pcr
carrageenan
contain
nasal
spray
alreadi
market
treatment
respiratori
viral
infect
differ
brand
name
countri
present
avail
effect
drug
treatment
post
exposur
prevent
influenza
ni
oseltamivir
zanamivir
worldwid
peramivir
japan
south
korea
sinc
largescal
use
blocker
prophylaxi
treatment
human
farm
current
circul
influenza
virus
alreadi
lack
sensit
drug
group
alreadi
shown
addit
therapeut
effect
combin
therapi
intranas
appli
iotacarrageenan
oral
administ
oseltamivir
lethal
infect
mice
treatment
start
hour
post
infect
hpi
due
promis
result
develop
concept
combin
carrageenan
ni
therapi
contrast
oseltamivir
need
activ
metabol
convers
zanamivir
directli
appli
activ
drug
also
administ
intranas
potenti
intranas
administr
zanamivir
investig
glaxosmithklin
seven
clinic
challeng
trial
volunt
infect
influenza
influenza
particip
got
intranas
appli
zanamivir
differ
dose
daili
dose
level
mg
mg
prophylaxi
therapi
challeng
trial
show
treatment
start
hour
post
viru
inocul
associ
prevent
laboratori
confirm
influenza
febril
ill
well
reduct
viral
titer
durat
shed
symptom
total
safeti
data
patient
intranas
applic
zanamivir
publish
evid
zanamivir
induc
advers
event
increas
frequenc
local
nasal
intoler
comparison
placebo
group
found
taken
togeth
combin
carrageenan
nasal
spray
provid
broad
antivir
activ
upper
respiratori
zanamivir
specif
antiinfluenza
drug
meet
exist
medic
need
treat
multipl
viral
infect
present
work
investig
therapeut
effect
combin
carrageenan
zanamivir
invitro
anim
model
kappacarrageenan
iotacarrageenan
purchas
fmc
biopolym
philadelphia
pa
ident
puriti
carrageenan
subtyp
molecular
weight
confirm
nmr
analysi
describ
elsewher
presenc
lambdacarrageenan
detect
limit
dri
polym
powder
dissolv
aqua
bidest
freseniu
kabi
austria
final
concentr
mgml
iota
mgml
kappacarrageenan
stock
solut
steril
filter
filter
paa
switzerland
store
room
temperatur
use
test
stock
solut
dilut
mixtur
contain
mgml
iotacarrageenan
mgml
kappacarrageenan
hereinaft
refer
carrageenan
zanamivir
purchas
powder
haosun
pharma
china
ident
puriti
confirm
nmr
analysi
zanamivir
either
dissolv
carrageenan
placebo
solut
follow
steril
filtrat
filter
sarstedt
germani
invivo
studi
zanamivir
contain
solut
freshli
prepar
madindarbi
canin
kidney
mdck
cell
obtain
american
type
cultur
collect
atcc
manassa
va
cultiv
incub
sanyo
japan
rel
humid
mdck
cell
grown
dulbecco
minim
essenti
dmem
high
glucos
medium
paa
austria
supplement
fetal
bovin
serum
fb
paa
austria
heat
inactiv
influenza
viru
ahansa
pdm
kindli
provid
peter
staeh
depart
virolog
univers
freiburg
germani
previous
describ
previous
publish
access
number
taxonomi
id
access
number
suppli
courtesi
martin
beer
institut
diagnost
virolog
friedrichloefflerinstitut
riem
germani
purchas
atcc
influenza
virus
propag
mdck
cell
influenza
medium
optipro
serum
free
medium
gibco
austria
supplement
mm
lglutamin
paa
austria
antibioticantimycot
mix
paa
austria
trypsin
sigma
aldrich
austria
determin
inhibitori
concentr
combin
effect
carrageenan
zanamivir
semiliquid
plaqu
assay
develop
well
tissu
cultur
plate
mdck
cellswel
seed
infect
confluenc
hour
later
serial
dilut
carrageenan
zanamivir
prepar
assay
medium
influenza
medium
without
trypsin
infect
virus
dilut
moi
pdm
aichi
respect
assay
medium
incub
room
temperatur
rt
min
serial
dilut
carrageenan
andor
zanamivir
respect
evalu
combin
effect
carrageenan
zanamivir
virus
dilut
assay
medium
contain
constant
concentr
either
carrageenan
zanamivir
substanc
serial
dilut
use
viru
incub
cell
infect
replicatescompound
dilut
respect
incub
rt
min
inoculum
remov
cell
incub
respect
concentr
investig
substanc
present
overlay
influenza
medium
carboxymethylcellulos
cmc
fluka
austria
hour
evolv
plaqu
evalu
methanolaceton
cell
fixat
immun
stain
antibodi
either
direct
influenza
nucleoprotein
abd
serotec
germani
pdm
hemagglutinin
abd
serotec
germani
analysi
done
hrp
label
detect
antibodi
thermo
scientif
germani
use
tmb
biolegend
germani
substrat
micropl
reader
nm
reduct
detect
signal
repres
reduct
number
size
plaqu
indic
suppress
viral
replic
infect
cultiv
immunostain
cell
stain
crystal
violet
solut
assess
condit
cell
layer
toxic
compound
valu
standard
deviat
calcul
sigmoid
dose
respons
model
use
xlfit
excel
addin
version
anim
experi
carri
accord
guidelin
european
convent
protect
vertebr
anim
use
experiment
scientif
purpos
austrian
law
anim
experi
anim
experi
approv
veterinari
univers
vienna
institut
ethic
committe
perform
austrian
feder
ministri
scienc
research
experiment
anim
licens
number
mice
purchas
janvier
lab
franc
maintain
standard
laboratori
condit
anim
facil
veterinari
univers
vienna
euthanasia
anesthesia
asphyxi
use
effort
made
minim
suffer
infect
experi
week
old
femal
mice
intranas
inocul
influenza
viru
solut
contain
plaqueform
unit
pdm
respect
subsequ
treatment
start
hpi
indic
differ
experi
treatment
perform
intranas
either
therapeut
solut
placebo
twice
per
day
day
therapi
either
carrageenan
contain
mgml
iotacarrageenan
mgml
kappacarrageenan
provid
daili
dose
mgkg
bodi
weight
bw
zanamivir
contain
either
zanamivir
provid
daili
dose
mgkg
bw
respect
combin
carrageenan
zanamivir
use
carrageenan
zanamivir
use
nontox
concentr
shown
mice
monitor
twice
daili
day
surviv
weight
loss
mortal
also
includ
mice
sacrif
ethic
consider
lost
initi
bodi
weight
confirm
viral
infect
anim
necropsi
score
lung
inflamm
mechan
underli
antivir
activ
ni
carrageenan
fundament
distinct
like
exhibit
differ
activ
toward
individu
influenza
viru
strain
result
combin
could
complement
provid
protect
broader
spectrum
influenza
viru
strain
individu
compound
test
hypothesi
investig
sensit
variou
influenza
viru
strain
zanamivir
carrageenan
adapt
plaqu
reduct
assay
semiliquid
overlay
mdck
cell
use
method
determin
zanamivir
carrageenan
influenza
virus
human
anim
origin
name
pdm
ahansa
low
pathogen
lp
lp
tabl
substanc
nontox
highest
test
concentr
zanamivir
carrageenan
neither
combin
furthermor
cmc
overlay
show
viru
inhibitori
effect
data
shown
inhibit
viral
replic
test
influenza
strain
achiev
substanc
howev
valu
vari
wide
depend
influenza
viru
strain
valu
zanamivir
rang
carrageenan
pdm
respect
see
tabl
result
demonstr
carrageenan
zanamivir
target
individu
influenza
strain
differ
extent
may
complement
provid
broader
antiinfluenza
activ
type
compound
interact
character
employ
isobologram
fig
describ
isobologram
graphic
compar
dose
two
compound
need
reach
inhibit
predict
dose
calcul
base
model
drug
addit
curv
linear
expect
addit
compound
interact
wherea
curv
progress
argu
synergist
antagonist
compound
interact
two
viru
strain
select
experi
one
sensit
carrageenan
pdm
one
least
sensit
case
isobologram
show
synergist
interact
carrageenan
zanamivir
fig
thu
shown
zanamivir
carrageenan
target
individu
influenza
virus
differ
effici
probabl
due
differ
antivir
strategi
result
combin
provid
synergist
activ
higher
protect
broader
spectrum
influenza
viru
strain
individu
compound
influenza
anim
model
mice
challeng
lethal
dose
respect
viru
treat
differ
regimen
comparison
vehicl
control
placebo
infect
treatment
twice
day
day
done
intranas
without
anesthesia
investig
whether
combin
zanamivir
carrageenan
efficaci
reduc
mortal
correspond
monotherapi
first
determin
minim
effect
dose
zanamivir
monotherapi
significantli
improv
surviv
time
infect
mice
lethal
infect
minim
effect
dose
zanamivir
monotherapi
rang
mgkg
bwday
data
shown
next
compar
antivir
activ
carrageenan
mgkg
bwday
zanamivir
mgkg
bwday
monotherapi
respect
combin
versu
placebo
treatment
surviv
rate
mice
treatment
start
hpi
shown
fig
placebo
treat
mice
die
day
also
monotherapi
group
lethal
observ
day
contrast
combin
therapi
led
surviv
depend
zanamivir
concentr
statist
analysi
show
zanamivir
monotherapi
mgkg
bwday
show
signific
benefit
p
wherea
monotherapi
mgkg
bwday
significantli
increas
surviv
rate
compar
placebo
treat
mice
p
zanamivir
concentr
experienc
signific
benefit
surviv
combin
carrageenan
p
similarli
combin
therapi
result
remark
increas
surviv
p
mg
p
mgkg
bwday
compar
carrageenan
monotherapi
statist
signific
differ
observ
combin
contain
mgkg
bwday
zanamivir
contain
mgkg
bwday
p
howev
trend
increas
surviv
rate
higher
zanamivir
concentr
evid
therefor
investig
combin
therapi
contain
mgkg
bwday
zanamivir
evalu
lethal
infect
mice
next
therapeut
potenti
combin
delay
therapi
start
hpi
versu
placebo
treatment
explor
surviv
rate
mice
shown
fig
placebo
treat
mice
die
day
also
group
treatment
start
hpi
lethal
found
contrast
combin
therapi
start
hpi
provid
statist
signific
enhanc
surviv
rate
comparison
placebotr
mice
p
summari
combin
two
effect
establish
monotherapi
result
significantli
enhanc
surviv
lethal
infect
mice
addit
combin
therapi
highli
effici
comparison
placebo
treatment
even
treatment
onset
hpi
next
minim
effect
dose
zanamivir
use
monotherapi
evalu
lethal
pdm
mous
model
follow
scheme
describ
experi
lowest
effect
dose
zanamivir
treatment
start
hpi
mgkg
bwday
combin
carrageenan
highli
effect
data
shown
follow
experi
therapeut
potenti
combin
therapi
start
hpi
investig
comparison
respect
placebo
treatment
shown
fig
surviv
rate
mice
treat
combin
therapi
highli
significantli
increas
comparison
placebo
group
p
differ
surviv
two
therapi
start
point
hpi
result
surviv
day
subsequ
experi
investig
effect
treatment
start
hpi
show
significantli
enhanc
surviv
placebo
treatment
data
shown
investig
antivir
effect
combin
carrageenan
ni
zanamivir
cell
cultur
studi
mous
influenza
infect
model
previous
shown
combin
therapi
iotacarrageenan
ni
oseltamivir
led
significantli
enhanc
surviv
mice
infect
comparison
respect
monotherapi
howev
oseltamivir
oral
administ
prodrug
convert
activ
form
metabol
process
therefor
develop
combin
nasal
spray
possibl
oseltamivir
instead
ni
appli
activ
chosen
develop
compound
combin
evalu
process
found
bind
effici
differ
carrageenan
subtyp
differ
influenza
strain
vari
combin
use
iota
kappacarrageenan
treatment
lethal
influenza
infect
mice
reveal
better
therapeut
effect
use
iotacarrageenan
alon
fig
thu
provid
broader
spectrum
activ
differ
influenza
viru
strain
mixtur
iota
kappacarrageenan
design
carrageenan
use
evalu
investig
effect
compound
combin
carrageenan
zanamivir
examin
inhibit
effici
individu
combin
influenza
virus
adapt
plaqu
reduct
assay
semiliquid
overlay
mdck
cell
combin
show
synergist
inhibit
viru
replic
invitro
assay
test
influenza
virus
fig
indic
physic
interact
polym
viru
disturb
inhibit
neuraminidas
zanamivir
confirm
invitro
test
examin
potenti
influenc
polym
neuraminidas
inhibit
activ
zanamivir
data
shown
henc
observ
synergist
effect
base
combin
two
distinct
underli
mechan
result
propos
combin
mechan
would
complement
provid
effici
protect
broader
spectrum
influenza
viru
strain
individu
compound
synergist
effect
also
shown
lethal
mice
model
fig
fig
pathogen
influenza
virus
mice
vari
depend
strain
adapt
host
depend
viru
dose
strain
influenza
virus
induc
lethal
infect
certain
mous
strain
usual
within
two
week
model
mice
challeng
intranas
lethal
dose
respect
viru
treat
differ
regimen
comparison
vehicl
control
placebo
model
earli
viru
replic
take
place
upper
respiratori
tract
viru
spread
lung
caus
lethal
pneumonia
effect
treatment
mortal
assess
comparison
placebotr
control
mice
invitro
test
influenza
strain
pdm
lp
particularli
interest
two
reason
first
highli
relev
pathogen
involv
recent
influenza
outbreak
pdm
associ
death
season
lp
carri
ha
close
relat
avian
influenza
viru
caus
death
octob
second
special
interest
carrageenanzanamivir
combin
approach
shown
differ
invitro
suscept
carrageenan
zanamivir
tabl
combin
thereof
fig
pdm
highli
sensit
inhibit
substanc
alon
requir
much
higher
concentr
carrageenan
zanamivir
respect
achiev
similar
inhibit
effici
therefor
viru
strain
chosen
explor
effici
combin
therapi
mous
model
establish
lethal
mous
model
virus
result
mean
surviv
day
lp
pdm
respect
result
good
accord
similar
alreadi
publish
lethal
influenza
model
model
lowest
effect
dose
zanamivir
treatment
start
hpi
found
mgkg
bwday
virus
concentr
rang
rel
high
comparison
publish
studi
howev
studi
done
anesthesia
differ
virus
prophylact
therapi
start
fact
higher
dose
ni
need
effect
treatment
therapi
start
hpi
alreadi
known
oseltamivir
nonetheless
also
data
much
higher
effect
concentr
mgkg
bwday
similar
concentr
zanamivir
mgkg
bwday
publish
well
found
combin
carrageenan
mgkg
bwday
zanamivir
use
treatment
infect
mice
result
significantli
enhanc
surviv
mice
comparison
monotherapi
fig
significantli
enhanc
surviv
compar
placebo
treat
group
also
found
delay
treatment
start
hpi
furthermor
pdm
model
combin
carrageenan
mgkg
bwday
zanamivir
show
statist
signific
enhanc
surviv
comparison
placebo
treatment
even
treatment
start
hpi
remark
find
sinc
ni
normal
effect
appli
hpi
find
support
develop
zanamivir
carrageenan
combin
approach
intranas
treatment
regim
incap
effect
treat
viru
infect
lung
primari
target
product
prophylaxi
therapi
uncompl
influenza
sinc
major
influenza
infect
caus
uncompl
ill
practic
case
influenza
start
infect
nasal
caviti
upper
respiratori
tract
therapeut
potenti
huge
howev
clinic
studi
requir
elucid
demonstr
potenti
propos
combin
therapi
combin
antivir
strategi
led
impress
achiev
combat
viral
diseas
like
hiv
particular
problem
antivir
resist
could
address
strategi
last
decad
concern
rais
increas
emerg
oseltamivir
resist
influenza
virus
augment
appear
virus
carri
mutat
neuraminidas
pdm
virus
confer
resist
oseltamivir
left
zanamivir
treatment
option
symptomat
patient
infect
oseltamivir
resist
influenza
strain
contrast
oseltamivir
resist
zanamivir
less
frequent
date
zanamivir
resist
influenza
detect
immunocompromis
patient
howev
lesson
learn
previou
antiinfluenza
intervent
result
occurr
resist
current
approv
drug
therefor
concern
comprehens
increas
zanamivir
use
may
also
lead
rapid
emerg
resist
overcom
threat
combin
antivir
inhibit
viru
replic
distinct
mechan
valid
strategi
check
possibl
gener
doubl
compound
escap
mutant
virus
passag
virus
presenc
increas
concentr
compound
combin
passag
mdck
cell
resist
compound
combin
test
influenza
viru
could
found
data
shown
howev
find
guarante
emerg
zanamivir
escap
mutant
complet
halt
summari
demonstr
antiinfluenza
mechan
singl
compound
complement
combin
provid
synergist
better
protect
broader
spectrum
influenza
virus
individu
compound
nasal
spray
contain
carrageenan
togeth
zanamivir
provid
easi
appli
treatment
upper
respiratori
tract
infect
patient
suspicion
influenza
infect
patient
would
benefit
fast
effici
treatment
uncompl
influenza
upper
respiratori
tract
due
faster
influenza
viru
clearanc
upper
respiratori
tract
independ
antivir
mechan
carrageenan
zanamivir
likelihood
develop
escap
mutat
zanamivir
reduc
individu
compound
abl
reduc
sever
andor
durat
influenza
ill
combin
expect
work
similarli
addit
due
broad
antivir
effect
carrageenan
patient
receiv
parallel
treatment
concomit
viral
infect
therefor
patient
benefit
decreas
probabl
develop
complic
consider
complic
known
accompani
influenza
viru
ill
combin
therapi
meet
urgent
medic
need
second
scope
combin
protect
newli
emerg
pandem
virus
time
identif
viru
follow
manufactur
distribut
vaccin
even
due
new
revers
genet
techniqu
less
time
product
vaccin
need
still
take
month
larg
quantiti
vaccin
avail
time
human
popul
protect
deceler
viral
spread
moment
avail
opportun
person
protect
hygien
measur
use
tamiflu
brand
name
oseltamivir
novel
protect
treatment
option
influenza
desper
need
base
encourag
result
mice
suggest
test
nasal
spray
contain
carrageenan
combin
neuraminidas
inhibitor
zanamivir
clinic
trial
prevent
treatment
uncompl
influenza
infect
